Fool.com
The World's Greatest Investing Community
Results 71 - 80 of 297 : Previous 4 5 6 7 8 9 10 11 12 Next
Merck-Schering Trumps Pfizer-Wyeth
Looking at this deal from several viewpoints, it's just better all around.
The latest good news from this company won't help the top line much.
Risperdal Consta doesn't live up to the agency's high standards.
That's what happens when a phase 3 drug doesn't work.
Are these companies dead -- or just dead-ish?
Merck and Schering-Plough are headed in opposite directions.
Australia's CSL uses technology and acquisitions to expand its influence.
The activist investor tries to board the Amylin train.
It isn't over yet. Here's how to prepare.
5 Stocks Resolved to Outperform
These stocks are tops in the month of January.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK